|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
SG11201400513PA
(en)
|
2011-09-08 |
2014-06-27 |
Yeda Res & Dev |
Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
|
|
EP2934532B1
(fr)
|
2012-12-20 |
2019-10-23 |
Purdue Research Foundation |
Cellules t exprimant un récepteur d'antigène chimérique et produits thérapeutiques anticancéreux
|
|
BR112017008042A2
(pt)
|
2014-10-20 |
2017-12-26 |
Juno Therapeutics Inc |
métodos e composições para dosagem em terapia de célula adotiva
|
|
KR20230005428A
(ko)
*
|
2015-05-28 |
2023-01-09 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위한 진단 방법
|
|
KR102349677B1
(ko)
|
2015-05-28 |
2022-01-12 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
AU2016291825B2
(en)
|
2015-07-16 |
2022-08-11 |
Yeda Research And Development Co. Ltd. |
Genetically modified anti-third party central memory T cells and use of same in immunotherapy
|
|
WO2017075451A1
(fr)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de pou2af1
|
|
WO2017075465A1
(fr)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de gata3
|
|
KR102427334B1
(ko)
|
2016-04-01 |
2022-08-03 |
카이트 파마 인코포레이티드 |
키메라 항원 및 t 세포 수용체 및 사용 방법
|
|
CA3019835A1
(fr)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methodes et compositions pour therapie par lymphocytes t car
|
|
MX395611B
(es)
|
2016-04-08 |
2025-03-25 |
Adaptimmune Ltd |
Receptores de celulas t.
|
|
WO2017180587A2
(fr)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Systèmes de biocircuits régulés
|
|
EP3465203B1
(fr)
|
2016-05-25 |
2026-03-18 |
The Council of the Queensland Institute of Medical Research |
Procédés d'immunothérapie
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018124766A2
(fr)
|
2016-12-28 |
2018-07-05 |
주식회사 녹십자랩셀 |
Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
|
|
ES3064681T3
(en)
*
|
2017-01-18 |
2026-04-28 |
Yeda Res & Dev |
Genetically modified veto cells and use of same in immunotherapy
|
|
CA3050299A1
(fr)
*
|
2017-01-20 |
2018-07-26 |
Atara Biotherapeutics, Inc. |
Methodes de traitement de la sclerose en plaques a l'aide de lymphocytes t autologues
|
|
AU2018219226B2
(en)
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
MX2019010171A
(es)
|
2017-02-27 |
2019-10-15 |
Juno Therapeutics Inc |
Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
WO2018169922A2
(fr)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Récepteurs antigéniques chimériques pour le mélanome et leurs utilisations
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(fr)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
Méthodes et compositions de détection et de modulation d'une signature génique de résistance à l'immunothérapie d'un cancer
|
|
CN110475571B
(zh)
*
|
2017-04-01 |
2023-04-04 |
Avm生物技术有限责任公司 |
细胞免疫疗法前细胞毒性预调理的替代
|
|
KR20190130024A
(ko)
|
2017-04-03 |
2019-11-20 |
카이트 파마 인코포레이티드 |
최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
US12097218B2
(en)
|
2017-05-26 |
2024-09-24 |
Kite Pharma, Inc. |
Methods of making and using embryonic mesenchymal progenitor cells
|
|
IL327498A
(en)
|
2017-06-02 |
2026-05-01 |
Juno Therapeutics Inc |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
EP3638218A4
(fr)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
Compositions et procédés ciblant le composant 3 du complément pour inhiber la croissance tumorale
|
|
WO2019014581A1
(fr)
|
2017-07-14 |
2019-01-17 |
The Broad Institute, Inc. |
Procédés et compositions pour moduler l'activité d'un lymphocyte cytotoxique
|
|
CA3076337A1
(fr)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
Compositions pour la therapie par lymphocytes t a recepteur antigenique chimerique et leurs utilisations
|
|
WO2019070755A1
(fr)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
Procédés et compositions pour détecter et moduler une signature génétique de résistance à l'immunothérapie dans un cancer
|
|
EP3691660A4
(fr)
|
2017-10-02 |
2021-07-07 |
Gamida-Cell Ltd. |
Expansion et utilisation de fractions de cellules nk étendues
|
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
|
CN111886015B
(zh)
*
|
2017-10-31 |
2024-04-26 |
艾洛基治疗公司 |
用于同种异体嵌合抗原受体t细胞的给药的方法和组合物
|
|
JP7357626B2
(ja)
|
2017-11-01 |
2023-10-06 |
ジュノー セラピューティクス インコーポレイテッド |
操作された細胞の治療用組成物を生成するためのプロセス
|
|
WO2019089858A2
(fr)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
|
|
WO2019094725A2
(fr)
|
2017-11-09 |
2019-05-16 |
Sangamo Therapeutics, Inc. |
Modification génétique de gène de protéine contenant sh2 inductible par la cytokine (cish)
|
|
US12171783B2
(en)
|
2017-11-13 |
2024-12-24 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas
|
|
WO2019094983A1
(fr)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Méthodes et compositions de traitement du cancer par ciblage de la voie clec2d-klrb1
|
|
KR102774451B1
(ko)
|
2017-11-14 |
2025-02-28 |
앱클론(주) |
항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
WO2019099707A1
(fr)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Récepteurs antigéniques chimériques modifiés et procédés d'utilisation
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
BR112020011223A2
(pt)
|
2017-12-08 |
2020-11-17 |
Juno Therapeutics Inc |
marcadores fenotípicos para terapia celular e mé-todos relacionados
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
AU2019206724A1
(en)
|
2018-01-15 |
2020-07-16 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1BB agonist
|
|
WO2019144095A1
(fr)
|
2018-01-22 |
2019-07-25 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Procédés d'utilisation de cellules t car
|
|
AU2019218729B2
(en)
|
2018-02-06 |
2025-12-04 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
|
|
WO2019165121A1
(fr)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Procédés d'activation et d'expansion de cellules tueuses naturelles et utilisations de celles-ci
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための配列決定法
|
|
US12186343B2
(en)
*
|
2018-03-09 |
2025-01-07 |
Crage Medical Co., Limited |
Method and composition for treating tumors
|
|
EP3765094A4
(fr)
|
2018-03-15 |
2021-12-22 |
KSQ Therapeutics, Inc. |
Compositions de régulation génique et procédés pour améliorer l'immunothérapie
|
|
US20210000876A1
(en)
|
2018-03-22 |
2021-01-07 |
Windmil Therapeutics, Inc. |
Prostate Cancer Specific Marrow Infiltrating Lymphocytes and Uses Thereof
|
|
WO2019191752A1
(fr)
*
|
2018-03-30 |
2019-10-03 |
Ohio State Innovation Foundation |
Procédés de pré-conditionnement de patients pour la thérapie à lymphocytes t
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
JP7584299B2
(ja)
|
2018-05-23 |
2024-11-15 |
ナショナル ユニバーシティ オブ シンガポール |
T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
|
|
KR102734592B1
(ko)
|
2018-06-01 |
2024-11-27 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 t 세포 요법
|
|
WO2019232542A2
(fr)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Procédés et compositions pour détecter et moduler des signatures géniques micro-environnementales à partir du lcr de patients présentant des métastases
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US20210155941A1
(en)
|
2018-06-22 |
2021-05-27 |
Kite Pharma Eu B.V. |
Compositions and methods for making engineered t cells
|
|
EP3826625A4
(fr)
*
|
2018-07-23 |
2022-08-24 |
Magenta Therapeutics, Inc. |
Utilisation d'un conjugué anticorps anti-cd5 -médicament (adc) dans une thérapie cellulaire allogénique
|
|
JP2021530545A
(ja)
*
|
2018-07-23 |
2021-11-11 |
マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. |
同種異系の細胞療法における抗−cd2抗体薬物コンジュゲート(adc)の使用
|
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US20210382068A1
(en)
|
2018-10-02 |
2021-12-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
EP3488851A1
(fr)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Thérapies immunoablatives
|
|
EP3632446B3
(fr)
|
2018-10-03 |
2024-01-24 |
AVM Biotechnology, LLC |
Thérapies immunoablatives
|
|
WO2020081730A2
(fr)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Méthodes et compositions pour moduler un microenvironnement
|
|
US12473345B2
(en)
*
|
2018-11-01 |
2025-11-18 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
|
|
GB201819540D0
(en)
|
2018-11-30 |
2019-01-16 |
Adaptimmune Ltd |
T cell modification
|
|
KR20250116790A
(ko)
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
WO2020131586A2
(fr)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Méthodes d'identification de néo-antigènes
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
JP2022518150A
(ja)
*
|
2019-01-07 |
2022-03-14 |
マジェンタ セラピューティクス インコーポレイテッド |
細胞療法での抗cd45抗体-薬物結合体(adc)の使用経験
|
|
KR20210137085A
(ko)
|
2019-03-05 |
2021-11-17 |
엔카르타, 인크. |
Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
|
|
WO2020186101A1
(fr)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Procédés de détection, compositions et méthodes de modulation des cellules de sarcome synovial
|
|
EP3942023A1
(fr)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions et méthodes de modulation de régulateurs métaboliques de pathogénicité de lymphocytes t
|
|
JP2022525928A
(ja)
*
|
2019-03-21 |
2022-05-20 |
ガミダ セル リミテッド |
併用療法における移植に適したnk細胞画分の増殖及び増殖nk細胞画分の使用
|
|
TW202042824A
(zh)
|
2019-03-27 |
2020-12-01 |
賓夕法尼亞大學董事會 |
Tn-MUC1嵌合抗原受體(CAR)T細胞療法
|
|
KR102947433B1
(ko)
|
2019-04-12 |
2026-04-06 |
씨4 테라퓨틱스, 인코포레이티드 |
이카로스 및 아이올로스의 트리시클릭 분해제
|
|
CN114206346A
(zh)
|
2019-05-03 |
2022-03-18 |
凯德药业股份有限公司 |
施用嵌合抗原受体免疫疗法的方法
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020243371A1
(fr)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Procédés et compositions pour la modulation de réponses immunitaires
|
|
CN114245807B
(zh)
|
2019-06-25 |
2025-05-02 |
吉利德科学公司 |
Flt3l-fc融合蛋白和使用方法
|
|
JP2022538974A
(ja)
|
2019-06-26 |
2022-09-07 |
マサチューセッツ インスチテュート オブ テクノロジー |
免疫調節融合タンパク質-金属水酸化物錯体およびその方法
|
|
AU2020307667A1
(en)
|
2019-06-27 |
2022-01-20 |
Crispr Therapeutics Ag |
Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
|
|
US20220282333A1
(en)
|
2019-08-13 |
2022-09-08 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
EP3786178A1
(fr)
|
2019-08-30 |
2021-03-03 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Constructions tcr spécifiques pour antigènes dérivés du virus d'epstein-barr (ebv)
|
|
US20220298501A1
(en)
|
2019-08-30 |
2022-09-22 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021061648A1
(fr)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Méthodes et compositions pour la stimulation de réponses de lymphocytes t endogènes
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
IL292665B2
(en)
|
2019-11-06 |
2026-02-01 |
Kite Pharma Inc |
Chimeric antigen receptor T cell therapy
|
|
CN112079934B
(zh)
*
|
2019-12-17 |
2021-01-29 |
合源生物科技(天津)有限公司 |
一种靶向cd19的嵌合抗原受体及其用途
|
|
US11865168B2
(en)
|
2019-12-30 |
2024-01-09 |
Massachusetts Institute Of Technology |
Compositions and methods for treating bacterial infections
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
US20230071910A1
(en)
*
|
2020-01-24 |
2023-03-09 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
|
|
IL295063A
(en)
|
2020-02-04 |
2022-09-01 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Chimeric antigen receptors (car) against dinitrophenol
|
|
WO2021168375A1
(fr)
|
2020-02-20 |
2021-08-26 |
Kite Pharma, Inc. |
Thérapie par lymphocytes t à récepteurs antigéniques chimériques
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
CA3172447A1
(fr)
|
2020-03-27 |
2021-09-30 |
Erik Hans MANTING |
Utilisation in vivo de cellules modifiees d'origine leucemique pour ameliorer l'efficacite d'une therapie cellulaire adoptive
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2022003568A1
(fr)
|
2020-06-30 |
2022-01-06 |
Dcprime B.V. |
Utilisation de cellules dérivées de la leucémie dans des vaccins contre le cancer de l'ovaire
|
|
AU2021369507B2
(en)
|
2020-10-28 |
2025-06-26 |
Kite Pharma, Inc. |
Flow cytometric method for characterization of t-cell impurities
|
|
US20220168407A1
(en)
|
2020-11-05 |
2022-06-02 |
Dcprime B.V. |
Use of tumor-independent antigens in immunotherapies
|
|
EP4262830A4
(fr)
|
2020-12-17 |
2025-01-15 |
Artiva Biotherapeutics, Inc. |
Traitement du cancer par des cellules nk et un anticorps ciblant cd20
|
|
EP4262829A4
(fr)
|
2020-12-17 |
2025-01-01 |
Artiva Biotherapeutics, Inc. |
Cellules tueuses naturelles multipliées et stimulées
|
|
WO2022150582A1
(fr)
|
2021-01-10 |
2022-07-14 |
Kite Pharma, Inc. |
Thérapie par lymphocytes t
|
|
KR20230135075A
(ko)
|
2021-01-22 |
2023-09-22 |
멘두스 비.브이. |
종양 백신접종 방법
|
|
JP2024507199A
(ja)
|
2021-02-20 |
2024-02-16 |
カイト ファーマ インコーポレイテッド |
免疫療法を選択するための遺伝子マーカー
|
|
AU2022227686A1
(en)
|
2021-02-25 |
2023-07-27 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
|
KR20240024047A
(ko)
|
2021-04-08 |
2024-02-23 |
아티바 바이오테라퓨틱스, 인크. |
Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법
|
|
AU2022254978A1
(en)
|
2021-04-08 |
2023-11-16 |
Artiva Biotherapeutics, Inc. |
Treatment of cancer with nk cells and a cd20 targeted antibody
|
|
KR20240024048A
(ko)
|
2021-04-08 |
2024-02-23 |
아티바 바이오테라퓨틱스, 인크. |
Nk 세포와 her2 표적 항체를 이용한 암 치료 방법
|
|
US20240366664A1
(en)
|
2021-04-08 |
2024-11-07 |
Artiva Biotherapeutics, Inc. |
Treatment of cancer with nk cells and an egfr targeted antibody
|
|
KR20230173179A
(ko)
|
2021-05-14 |
2023-12-26 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 t세포 요법
|
|
WO2022245671A1
(fr)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Méthodes d'utilisation de protéines de fusion flt3l-fc
|
|
MX2024003887A
(es)
|
2021-10-14 |
2024-07-09 |
Arsenal Biosciences Inc |
Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
|
|
EP4433512A4
(fr)
|
2021-11-19 |
2025-12-31 |
Univ Pennsylvania |
Antigène cd45 à spécificité pan-leucocytaire génétiquement modifié pour faciliter une thérapie de lymphocytes t car
|
|
CN118742810A
(zh)
|
2022-02-15 |
2024-10-01 |
凯德药业股份有限公司 |
从免疫疗法预测不良事件
|
|
US20240002800A1
(en)
|
2022-05-16 |
2024-01-04 |
Mendus B.V. |
Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
|
|
TWI882495B
(zh)
|
2022-10-28 |
2025-05-01 |
美商凱特製藥公司 |
用於將免疫療法最佳化之因素
|
|
JP2026508791A
(ja)
|
2022-10-28 |
2026-03-13 |
カイト ファーマ インコーポレイテッド |
免疫療法の有効性及び永続的奏効の改善
|
|
JP2025538424A
(ja)
*
|
2022-11-16 |
2025-11-28 |
ンカルタ・インコーポレイテッド |
併用療法の投与レジメン
|
|
DE102022132083B4
(de)
|
2022-12-02 |
2024-08-22 |
Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) |
Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
|
|
DE102022132084B4
(de)
|
2022-12-02 |
2024-08-22 |
Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) |
Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
|
|
DE102022132082B4
(de)
|
2022-12-02 |
2024-08-08 |
Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) |
Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
|
|
WO2024124044A1
(fr)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions et procédés ciblant sat1 pour améliorer l'immunité antitumorale pendant la progression d'une tumeur
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向psma及ca9之系統
|
|
CN120957741A
(zh)
|
2023-03-13 |
2025-11-14 |
宾夕法尼亚大学董事会 |
用于肿瘤治疗的car修饰剂的产生
|
|
CN120917153A
(zh)
|
2023-03-17 |
2025-11-07 |
凯德药业股份有限公司 |
肿瘤微环境对免疫疗法疗效的影响
|
|
WO2024211852A1
(fr)
*
|
2023-04-07 |
2024-10-10 |
Fate Therapeutics, Inc. |
Cellule nk dérivée d'ipsc pour traitement de lymphome
|
|
WO2024243428A2
(fr)
*
|
2023-05-24 |
2024-11-28 |
Instil Bio Inc. |
Utilisation de constructions de fusion pour thérapie cellulaire
|
|
EP4712987A2
(fr)
*
|
2023-06-27 |
2026-03-25 |
Nkarta, Inc. |
Méthodes de traitement utilisant des immunothérapies ciblant cd19
|
|
WO2025059533A1
(fr)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Enzymes crispr et systèmes
|
|
WO2025096419A1
(fr)
|
2023-10-31 |
2025-05-08 |
Lyell Immunopharma, Inc. |
Lymphocytes t comprenant un récepteur antigénique chimérique ciblant le facteur de croissance transformant bêta et un récepteur de lymphocytes t ciblant un antigène tumoral, et leur utilisation
|
|
US20250161361A1
(en)
|
2023-11-01 |
2025-05-22 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
WO2025097055A2
(fr)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions et méthodes d'utilisation de lymphocytes t en immunothérapie
|
|
WO2025117544A1
(fr)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Molécule de guidage oméga ingéniérisée et compositions iscb, systèmes et procédés d'utilisation associés
|
|
US20250290154A1
(en)
|
2024-03-04 |
2025-09-18 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|
|
US20260224626A1
(en)
|
2024-11-04 |
2026-08-06 |
Kite Pharma, Inc. |
Biomarkers related to immunotherapy efficacy
|